John Borgeson

John Borgeson is our Chief Financial Officer and has served in this position since June 2014. Borgeson brings over 25 years of pharmaceutical industry experience in finance, strategy and operations on a global scale. Previously Borgeson was a Vice President of Finance at Pfizer and a member of Pfizer’s Global Financial Leadership Team. Borgeson’s roles at Pfizer included CFO for Pfizer’s biotherapeutics division and corporate tax executive with responsibility for US and Europe. Under Borgeson’s leadership, Pfizer completed a transformational restructuring of the global tax group that was replicated by other Fortune 50 companies.

Borgeson has more recently led finance for a variety of private biotech companies, including Labrys Biologics, which was acquired by Teva Pharmaceuticals for $825 million. He was also CFO of venBio, a venture capital firm with a strong track record in biotechnology investing. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant.

He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).

John Borgeson is the Chief Financial Officer at ALX Oncology, based in United States, North America. With a background in Biotechnology, John Borgeson has a rich history of leadership and innovation.John Borgeson studied MBA unknown at Rochester Institute of Technology. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.